Tetrylammonium

Tetrylammonium

SCHEMBL331444

CC[N+](CC)(CC)CC.CS(=O)(=O)O

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol

The experimentally established mechanism targets of Tetrylammonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SLC6A4 known ✓ P31645 1/20 0.31
TSHR P16473 1/20 0.53
NFKB1 P19838 1/20 0.53
KCNA1 Q09470 1/20 0.53
KDM4E B2RXH2 2/20 0.50
PMP22 Q01453 1/20 0.50
ATM Q13315 1/20 0.50
CA2 P00918 3/20 0.37
CYP3A4 P08684 1/20 0.31
CA5A P35218 1/20 0.31
CA5B Q9Y2D0 1/20 0.31
CA1 P00915 3/20 0.31
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetrylammonium SCHEMBL36704 0.90 TSHR (0.57) TSHRNFKB1KCNA1KDM4EPMP22
Tetrylammonium SCHEMBL27869205 0.90 TSHR (0.57) TSHRNFKB1KCNA1KDM4EPMP22
Tetrylammonium SCHEMBL331298 0.87 TSHR (0.53) TSHRNFKB1KCNA1KDM4EPMP22
Tetrylammonium SCHEMBL3643966 0.87 TSHR (0.53) TSHRNFKB1KCNA1KDM4EPMP22
Tetrylammonium SCHEMBL28602155 0.87 TSHR (0.53) TSHRNFKB1KCNA1KDM4EPMP22
Tetrylammonium SCHEMBL36661 0.84 TSHR (0.50) TSHRNFKB1KCNA1KDM4EPMP22
Tetrylammonium SCHEMBL36705 0.84 TSHR (0.50) TSHRNFKB1KCNA1KDM4EPMP22
Tetrylammonium SCHEMBL27732100 0.84 TSHR (0.50) TSHRNFKB1KCNA1KDM4EPMP22
Tetrylammonium SCHEMBL8645725 0.84 TSHR (0.50) TSHRNFKB1KCNA1KDM4EPMP22
Tetrylammonium SCHEMBL3643961 0.81 TSHR (0.47) TSHRNFKB1KCNA1KDM4EPMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260015560-A1 COMPOSITIONS FOR POST-CMP CLEANING OF MICROELECTRONIC DEVICES ENTEGRIS INC (US) 2026-01-15 US claimed
CN-122079810-A Aromatic diamine and polyimide containing amido, preparation method and application thereof 2026-05-26 CN disclosed
US-20260015560-A1 COMPOSITIONS FOR POST-CMP CLEANING OF MICROELECTRONIC DEVICES ENTEGRIS INC (US) 2026-01-15 US disclosed
EP-4649083-A1 COMPOUNDS DERIVED FROM DIHYDROPIRIDINES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS AND METHOD OF TREATMENT OF MUSCLE DISORDERS COMPRISING ADMINISTRATION OF SAID COMPOSITIONS Universidad de Chile (CL) 2025-11-19 EP disclosed
US-20250049953-A1 TREATMENT AND METHOD FOR INHIBITING LATE NA CURRENT UNIV COLUMBIA (US) 2025-02-13 US disclosed
WO-2024150029-A1 COMPOUNDS DERIVED FROM DIHYDROPIRIDINES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS AND METHOD OF TREATMENT OF MUSCLE DISORDERS COMPRISING ADMINISTRATION OF SAID COMPOSITIONS UNIVERSIDAD DE CHILE (CL) 2024-07-18 WO disclosed
CN-107209146-B Electrochemical gas sensor and electrolyte for electrochemical gas sensor 德尔格安全股份两合公司 2024-03-12 CN disclosed
WO-2023154933-A1 TREATMENT AND METHOD FOR INHIBITING LATE NA CURRENT THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2023-08-17 WO disclosed
US-20220397567-A1 NOVEL APPROACH FOR INCREASING CONTRACTILITY IN PATIENTS WITH SYSTOLIC HEART FAILURE UNIV COLUMBIA (US) 2022-12-15 US disclosed
US-20220267288-A1 CARDIAC THERAPEUTIC NATIONAL UNIVERSITY OF SINGAPORE (SG) 2022-08-25 US disclosed
CN-102977309-A Polymerizable composition for polythiourethane optical material, polythiourethane optical material obtained from the polymerizable composition, and polymerization catalyst for polythiourethane optical material MITSUI CHEMICALS INC 2013-03-20 CN disclosed
US-8304507-B2 Polymerizable composition for polythiourethane optical material, polythiourethane optical material obtained from the polymerizable composition, and polymerization catalyst for polythiourethane optical material MITSUI CHEMICALS, INC. (JP) 2012-11-06 US disclosed
EP-2407498-A2 Polymerizable composition for polythiourethane optical material, polythiourethane optical material obtained from the polymerizable composition, and polymerization catalyst for polythiourethane optical material Mitsui Chemicals, Inc. (JP) 2012-01-18 EP disclosed
CN-102066450-A Polymerizable composition for polythiourethane optical material, polythiourethane optical material obtained from the polymerizable composition, and polymerization catalyst for polythiourethane optical material MITSUI CHEMICALS INC 2011-05-18 CN disclosed
US-20110112269-A1 POLYMERIZABLE COMPOSITION FOR POLYTHIOURETHANE OPTICAL MATERIAL, POLYTHIOURETHANE OPTICAL MATERIAL OBTAINED FROM THE POLYMERIZABLE COMPOSITION, AND POLYMERIZATION CATALYST FOR POLYTHIOURETHANE OPTICAL MATERIAL MITSUI CHEMICALS, INC. (JP) 2011-05-12 US disclosed
EP-2295484-A1 POLYMERIZABLE COMPOSITION FOR POLYTHIOURETHANE OPTICAL MATERIAL, POLYTHIOURETHANE OPTICAL MATERIAL OBTAINED FROM SAME POLYMERIZABLE COMPOSITION, AND POLYMERIZATION CATALYST FOR POLYTHIOURETHANE OPTICAL MATERIAL Mitsui Chemicals, Inc. (JP) 2011-03-16 EP disclosed
US-7833643-B2 Neutral protic-salt electrolytes and protic-salt imbibed polymer membranes for high temperature fuel cell applications ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2010-11-16 US disclosed
US-20070122675-A1 Neutral Protic-Salt Electrolytes and Protic-Salt Imbibed Polymer Membranes for High Temperature Fuel Cell Applications ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY 2007-05-31 US disclosed
US-5110975-A ISOCYANATOALKYL SULPHONATES AND A PROCESS FOR THEIR PREPARATION BAYER AKTIENGESELLSCHAFT (DE) 1992-05-05 US disclosed
US-4225498-A Preparation of N-substituted oligo-imides RHONE-POULENC INDUSTRIES (FR) 1980-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220267288-A1 CARDIAC THERAPEUTIC TNNT2, TNNI3, RYR2 SLC6A4 4563/4885TSHR 3155/4885NFKB1 2505/4885
US-20260015560-A1 COMPOSITIONS FOR POST-CMP CLEANING OF MICROELECTRONIC DEVICES TET2, ASIC1, PIEZO1 SLC6A4 1219/4885TSHR 2647/4885NFKB1 2500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.